Bookmark and share the address of UKRAINE ENGLISH NEWS on your social bookmarking website
Most users ever online was 229 on Sat Aug 08, 2015 11:03 pm
Lilly pharmaceutical company has released data suggesting its Solanezumab drug can cut the rate of progression by around 34 percent in the early stages.
The findings were presented by the University of Southern California’s Paul Aisen at the Alzheimer’s Association International Conference.
“It suggests that starting therapy early is important. That you will be modifying the underlying disease in a way that accrues benefit with time, so that the earlier you start, the greater the benefit and if you start therapy later, you don’t catch up.”.............
To read further go to this link: euronews.com
SCROLL UP OR DOWN FOR ADDITIONAL ARTICLES!